Written by Amal Allam
Saturday, February 18, 2023 12:15 PM
The US Food and Drug Administration said:FDAShe agreed to a company drug Called Pharmaceuticals To treat an advanced eye disorder that is one of the leading causes of blindness worldwide.
According to the Reuters website, the drug slowed the progression of geographical atrophy of the eye(GA) It is the only treatment approved by the US Food and Drug Administration (FDA) to this disorder.
The company told Reuters, “The new drug will be listed at $2,190 per vial, in line with recently approved treatments against… VEGF It is a vascular endothelial growth factor.”
Anti-VEGF therapies prevent or regulate the formation and growth of blood vessels, and are used as a treatment for cancer andAge-related macular degenerationGeographical atrophy of the eye GA It is a chronic progressive condition that tends to occur in the late stage of age-related macular degeneration. Loss of retinal tissue can lead to vision loss. The disease affects 8 million patients worldwide, and about 20% of individuals with age-related macular degeneration.
And the agency’s website stated that the drug is expected to be available at the beginning of March through specialized distributors and specialized pharmacies in the United States.
